Can the pharmaceutical industry reduce attrition rates?

Nature Reviews Drug Discovery

Volumn 3, Issue 8, 2004, Pages 711-715

  Kola, Ismail ^a   Landis, John ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; COMMERCIAL PHENOMENA; CONSUMER; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; ECONOMIC ASPECT; GOVERNMENT; HEALTH CARE COST; HUMAN; NONHUMAN; POLITICS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; CLINICAL TRIAL; DRUG DESIGN; ECONOMICS; PHARMACOKINETICS;

CLINICAL TRIALS; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; HUMANS; PHARMACOKINETICS;

EID: 4344645978     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1470     Document Type: Article

References (12)

1. Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5-10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
2. Franz, S. 2003 approvals: a year of innovation and upward trends. Nature Rev. Drug Discov 3, 103-105 (2004).
3. Accenture Consulting. High performance drug discovery: an operating model for a new era. Accenture (2001).
4. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
5. Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19-20 June (2002).
6. Booth, B., Glassman, R. & Ma, P. Oncology's trials. Nature Rev. Drug Discov. 2, 609-610 (2003).
7. Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03-202 R (CMR International Surrey, UK, 2003).
8. Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
9. Roberds, S. L. et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317-1324 (2001).
10. Gowen, et al. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14, 1654-1663 (1999).
11. Lazner, F., Gowen, M. & Kola, I. An animal model for pycnodysostosis: the role of cathepsin K in bone remodeling. Mol. Med. Today 5, 413-414 (1999).
12. Ma, P. & Zemmel, R. Value of novelty? Nature Rev. Drug Discov. 1, 571-572 (2002).